Table 1 Baseline characteristics of study population after propensity-score matching
Characteristics | Statin users | Statin non-users | PÂ value |
|---|---|---|---|
(n = 500) | (n = 500) | ||
Age (years, mean ± sd) | 60.0 ± 10.9 | 61.2 ± 13.8 | 0.1241 |
Women | 281 (56.2) | 289 (57.8) | 0.6094 |
Medical history | |||
 Cerebrovascular disease | 75 (15.0) | 76 (15.2) | 0.9296 |
 Ischemic heart disease | 115 (23.0) | 102 (20.4) | 0.3186 |
 Other heart disease | 112 (22.4) | 101 (20.2) | 0.3955 |
 Rheumatoid arthritis | 15 (3.0) | 18 (3.6) | 0.5954 |
 Liver disease | 68 (13.6) | 68 (13.6) | 1.0000 |
 Kidney disease | 20 (4.0) | 25 (5.0) | 0.4456 |
 Hypertension | 103 (20.6) | 82 (16.4) | 0.0872 |
Medication | |||
 Antihypertensive drugs | 216 (43.2) | 194 (38.8) | 0.1572 |
  ARB | 110 (22.0) | 112 (22.4) | 0.8790 |
  ACEI | 19 (3.8) | 20 (4.0) | 0.8702 |
  Beta blocker | 35 (7.0) | 33 (6.6) | 0.8016 |
  CCB | 124 (24.8) | 120 (24.0) | 0.7684 |
  Antihypertensive diuretic | 4 (0.8) | 2 (0.4) | 0.4128 |
  Other antihypertensive drugs | 57 (11.4) | 57 (11.4) | 1.0000 |
   Lipid-lowering drugs other than statins | |||
  Fibrate | 13 (2.6) | 15 (3.0) | 0.7014 |
  Bile acid sequestrant | 4 (0.8) | 4 (0.8) | 1.0000 |
  Nicotinic acid | 7 (1.4) | 5 (1.0) | 0.5613 |
  Cholesterol absorption inhibitor | 1 (0.2) | 0 (0.0) | 0.3171 |
  Other lipid-lowering drugs | 16 (3.2) | 13 (2.6) | 0.5718 |
 Antithrombotic drug | 182 (36.4) | 193 (38.6) | 0.4724 |
 Liver disease therapeutic | 11 (2.2) | 9 (1.8) | 0.6514 |
 Kidney disease therapeutic | 4 (0.8) | 6 (1.2) | 0.5250 |
 Proton pump inhibitor | 92 (18.4) | 79 (15.8) | 0.2749 |
 H2 blocker | 60 (12.0) | 70 (14.0) | 0.3471 |
 NSAID | 129 (25.8) | 131 (26.2) | 0.8854 |
 Non-thiazide diuretic | 35 (7.0) | 34 (6.8) | 0.9007 |
 Antiarrhythmic drug | 45 (9.0) | 46 (9.2) | 0.9124 |
Laboratory parameters | |||
 Triglyceride (mg/dL, mean ± sd) | 134.7 ± 65.4 | 134.4 ± 75.8 | 0.9494 |
 Casual glucose (mg/dL, mean ± sd) | 102.2 ± 10.0 | 101.8 ± 10.6 | 0.6250 |